Guanabenz hydrochloride NEW
| Price | $38 | $73 | $107 |
| Package | 50mg | 100mg | 200mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Guanabenz hydrochloride | CAS No.: 23113-43-1 |
| Purity: 99.59% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Guanabenz hydrochloride |
| Description | Guanabenz hydrochloride (NE56490) is an orally active α2-adrenoceptor agonist with hypotensive effects. |
| In vivo | Maximum concentrations of guanabenz hydrochloride in plasma (1.2 to 5.2 ng/ml) reached 2 to 5 hours after administration of capsules containing 16 or 32 mg of 14C-labelled guanabenz hydrochloride. Guanabenz hydrochloride was 90% bound to human plasma proteins. Guanabenz hydrochloride competed for imidazoline I2-binding sites in brown adipose tissue with Ki of 97 nM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.48 mM), Sonication is recommended. DMSO : 55 mg/mL (205.58 mM), Sonication is recommended. |
| Keywords | α2-adrenoceptor | Parasite | NE-56490 | NE 56490 | Inhibitor | inhibit | high blood pressure | Guanabenz hydrochloride | Guanabenz | Beta Receptor | antiparasitic | antihypertensive | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Flubendazole | Gum arabic | Kojic acid | Urethane | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | Fenpyroximate | Methylene Blue trihydrate | Coumaran | Benzimidazole |
| Related Compound Libraries | Anti-Parasitic Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2785.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2021-08-10 | |
| $2.00 |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY